Recce Pharmaceuticals (ASX:RCE) YoY EBITDA Growth : 25.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Recce Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 25.00%.

Recce Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.04.

Recce Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Recce Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals YoY EBITDA Growth Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

YoY EBITDA Growth

Get a 7-Day Free Trial

-55.56

-14.29

-162.50

27.38

-18.03

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial											52.00	-58.82	-44.44	25.93	25.00

Recce Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Recce Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

	YoY EBITDA Growth (A: Jun. 2023 )
=	(EBITDA per Share (A: Jun. 2023 )	-	EBITDA per Share (A: Jun. 2022 ))	/	\| EBITDA per Share (A: Jun. 2022 ) \|
=	(-0.072	-	-0.061)	/	\| -0.061 \|
=	-18.03 %

Recce Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.039	-	-0.052)	/	\| -0.052 \|
=	25.00 %

Recce Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals (ASX:RCE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines